An organ transplant is one of the most expensive and consequential procedures Medicare covers—and one where the coverage rules are genuinely confusing. The surgery itself, the anti-rejection drugs that follow, and the lifelong follow-up are split across Part A, Part B, and Part D in ways that surprise most beneficiaries. Getting this right matters enormously, because stopping anti-rejection drugs means losing the organ. This guide explains how Medicare covers kidney, liver, heart, lung, and other transplants, the all-important immunosuppressant drug rules, and the recent law that closed a dangerous gap for kidney patients.

The Transplant Itself: Part A and Part B

A covered transplant must be performed at a Medicare-approved transplant center. The procedure splits across two parts of Medicare:

  • Part A covers the inpatient hospital stay—the transplant surgery, the hospital room, and the costs of acquiring the donor organ. This is subject to the $1,676 benefit-period deductible (2026). For the full inpatient rules, see our Part A coverage guide.
  • Part B covers physician services, pre-transplant evaluation, lab work, and outpatient follow-up care—at 80 percent after the $257 deductible (2026), leaving 20 percent coinsurance.

Importantly, the living donor’s costs related to the transplant are covered under the recipient’s Medicare at no cost to the donor. Medicare pays for the donor’s evaluation, surgery, and recovery care when the recipient is a Medicare beneficiary.

How You Qualify—Including ESRD

Most transplant recipients already have Medicare through age (65+) or disability. But kidney patients have a special path: end-stage renal disease (ESRD) triggers Medicare eligibility at any age. This is the same rule covered in our chronic kidney disease guide—a 40-year-old on dialysis or needing a kidney transplant can qualify for Medicare specifically because of kidney failure.

This ESRD eligibility is what created the historic immunosuppressant problem—and the recent fix—described below.

Immunosuppressant Drugs: The Part B vs. Part D Split

After a transplant, you take anti-rejection (immunosuppressant) drugs for the life of the organ—tacrolimus (Prograf), cyclosporine, mycophenolate (CellCept), prednisone, sirolimus, and others. How Medicare pays depends on a specific rule:

  • Part B covers immunosuppressant drugs at 20 percent coinsurance (no annual cap)—but only if Medicare paid for the transplant that you’re being treated after. This is the standard path for most transplant recipients.
  • Part D covers immunosuppressants (capped at $2,000 per year) when Part B’s specific conditions aren’t met—for example, if you had the transplant before you had Medicare, or it wasn’t Medicare-covered.

This is a crucial and counterintuitive twist on the usual Part B vs. Part D drug split. For most expensive drugs, the Part D cap is the cheaper side. But here, Part B coverage of immunosuppressants is the default for Medicare-paid transplants, and that 20 percent coinsurance has no annual ceiling unless you have supplemental coverage. Because these drugs are taken for decades, that uncapped coinsurance is a real, recurring exposure—making Medigap Plan G especially valuable for transplant recipients.

You generally cannot choose to route the drugs through Part D’s cap if they qualify for Part B; Medicare’s rules determine which part pays. The practical answer to the uncapped Part B coinsurance is supplemental coverage, not part-switching. See our Part D explainer for how the drug benefit works overall.

The 2023 Lifetime Immunosuppressant Benefit (Part B-ID)

For decades, kidney patients faced a cruel cliff. If you qualified for Medicare only because of ESRD, your Medicare ended 36 months after a successful kidney transplant—and with it, coverage of the immunosuppressant drugs that kept the kidney alive. Patients who couldn’t afford the drugs risked losing the transplanted kidney and returning to dialysis.

As of January 1, 2023, that gap is closed. A federal benefit—officially the Medicare Part B Immunosuppressive Drug benefit (Part B-ID)—lets people whose Medicare would otherwise end keep immunosuppressant drug coverage for life. You pay a separate, smaller monthly premium for this limited benefit, and it covers only the immunosuppressant drugs (not other medical care). It applies to those who don’t have other coverage such as Medicaid, a group health plan, or TRICARE.

If you or a family member had a kidney transplant and Medicare was ending at the 36-month mark, this benefit is what prevents losing the organ to drug costs. It’s one of the most important recent changes in transplant coverage.

Follow-Up Care, Rejection, and Re-Transplant

Transplant care doesn’t end at discharge:

  • Lab monitoring—frequent blood tests to check organ function and drug levels are covered under Part B (clinical lab tests at zero coinsurance).
  • Treatment of rejection episodes—hospitalization under Part A, infused anti-rejection therapy under Part B.
  • Specialist visits—transplant nephrology, hepatology, or cardiology under Part B at 20 percent coinsurance.
  • Re-transplant is covered if a transplanted organ fails, subject to the same approval and cost rules.

How Coverage Differs by Organ

Medicare covers transplants of the kidney, heart, liver, lung, pancreas, intestine, and combinations (such as heart-lung or kidney-pancreas) when performed at an approved center and deemed medically necessary. The structure—Part A surgery, Part B follow-up, immunosuppressants usually under Part B—is the same across organs, but a few distinctions matter:

  • Kidney transplant is unique because of the ESRD eligibility pathway and the Part B-ID lifetime immunosuppressant benefit described above. It is also by far the most common transplant in the Medicare population.
  • Heart and lung transplants involve longer, more complex inpatient stays under Part A and intensive post-transplant monitoring, but the drug rules are identical.
  • Liver transplant often follows years of managing cirrhosis or chronic viral hepatitis, and the same lifelong immunosuppressant coinsurance applies.

In every case, the anti-rejection drugs are the recurring lifetime cost, and the organ you received doesn’t change how Medicare pays for them.

A Concrete Cost Picture

Imagine a kidney transplant recipient on Original Medicare with no supplement. Tacrolimus and mycophenolate under Part B might carry a combined cost where the 20 percent coinsurance runs several hundred to over a thousand dollars a year, every year, indefinitely—plus 20 percent on every follow-up visit and any infused treatment for a rejection scare. Over a decade, that uncapped coinsurance can total many thousands of dollars. A recipient with Medigap Plan G pays that 20 percent through the plan and owes essentially just the annual Part B deductible. Across the lifetime of a transplant, the supplement frequently pays for itself many times over.

Why Supplemental Coverage Is Decisive for Transplant Patients

Transplant recipients combine a large Part A inpatient event with lifelong, uncapped Part B costs—the immunosuppressant coinsurance, recurring specialist visits, and any infused treatment for rejection. Under Original Medicare alone, none of that 20 percent has an annual ceiling.

  • Medigap Plan G pays that 20 percent with no annual limit, turning unpredictable lifelong drug and follow-up coinsurance into essentially just the small Part B deductible each year. For transplant patients specifically, this is often the single most valuable financial decision.
  • Medicare Advantage caps annual in-network out-of-pocket but adds prior authorization and network limits—a serious consideration when you depend on a specific Medicare-approved transplant center and transplant pharmacy. Weigh the trade-offs in our Medicare Advantage vs. Original Medicare comparison and the cost-focused breakdown.

Help With Costs

  • Medicare Savings Programs can pay your Part B premium and, at the QMB level, your Part B coinsurance—directly relieving the uncapped immunosuppressant exposure.
  • Extra Help lowers Part D drug costs for any of your medications that fall under Part D.
  • Transplant center social workers and organ-specific foundations (such as the American Kidney Fund) help with premiums, travel, and drug copays.

The Bottom Line

Medicare covers organ transplants comprehensively—the surgery and donor costs under Part A, the physician and follow-up care under Part B, and the lifelong immunosuppressant drugs, usually under Part B at an uncapped 20 percent coinsurance. The 2023 Part B-ID benefit closed the old 36-month cliff that once threatened kidney recipients with losing their organ to drug costs. Your largest financial risk is that uncapped, decades-long Part B coinsurance on anti-rejection drugs and follow-up—exactly what Medigap Plan G is built to eliminate. For the broader planning picture, see our guide to healthcare costs in retirement.